Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | CPX-351 with venetoclax in R/R AML: results of a Phase Ib study

Alex Bataller • 11 Dec 2023
ASH 2023
Acute Myeloid Leukemia Leukemia Cladribine CPX-351 Daunorubicin Venetoclax

Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the findings of a Phase Ib dose-escalation study investigating liposome-encapsulated daunorubicin-cytarabine (CPX-351) in combination with venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) (NCT03629171). The results of this study were promising, with a tolerable safety profile and encouraging responses in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alex Bataller

1:04
CLAD-LDAC-Ven induction therapy in AML: insights from a Phase II trial
Alex Bataller • 11 Dec 2023
0:44
Unmet needs in AML: TP53 mutations and maintenance therapy
Alex Bataller • 11 Dec 2023
1:09
DEC-C plus venetoclax in HR-MDS and CMML: an analysis using different response criteria
Alex Bataller • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals